APT Therapeutics, Inc.

Saint Louis, MO 63108

SBIR Award Summary

Total Number of Awards 28
Total Value of Awards $11.1MM
First Award Date 01/16/04
Most Recent Award Date 09/15/17

Key Personnel

Last Name Name Awards Contact
Jeong Soonseog Jeong 1
Chen Ridong Chen 27

28 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/15/17 - 08/31/18

Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes and the leading cause of end-stage renal disease in Western and Asian countries. The current medical management of diabetes to prevent its complications include tight glycemic control and strict management of blood pressure, these established treatments d...

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 08/01/17 - 07/31/18

Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong Abstract There remains a crucial unmet medical need in acute ischemic stroke (AIS) treatment: Approximately 20% of 795,000 patients die within one year and 15-30% are permanently disabled, making AIS the fourth leading cause of death and the leading cause of adult disabi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/18/17 - 03/31/18

Adjunctive antithrombotic treatment with dual antiplatelet therapy (aspirin + P2Y12 antagonist) plus anticoagulant (heparin or bivalirudin) is a guideline mandated for percutaneous coronary intervention (PCI) patients. Despite aggressive antithrombotic therapy, however, myocardial perfusion after PCI remains inadequate in many patients. Reocc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/14/16 - 08/31/17

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that affects at least 1.5 million Americans. Current immunosuppressive treatments are effective but can be accompanied by infections and toxicity, especially when applied over a longer period of time. Hence, there remains a significant unmet need for safe and more effective...

Phase SBIR

Agency: Department of Health & Human Services
Topic: PAR-16-027
Budget: 08/01/16 - 07/31/17

Principal Investigator/Program Director (Last, First, Middle: Chen, RidongAbstract There remains a crucial unmet medical need in acute ischemic stroke (AIS) treatment: Approximately 20%of 795,000 patients die within one year and 15-30% are permanently disabled, making AIS the fourth leadingcause of death and the leading cause of adult disability...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 05/01/16 - 04/30/17

? DESCRIPTION (provided by applicant): Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong Abstract Type-2 diabetes (T2D) is a leading cause of cardiovascular disease, renal failure, blindness, amputations and hospitalization. Up to 80% of T2D patients are overweight or obese, which induces chronic, low-grade inflammatio...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/20/15 - 08/31/16

DESCRIPTION (provided by applicant): Type 1 diabetes is an immune-mediated disease in which insulin-producing beta cells are destroyed, resulting in life-long dependence on exogenous insulin. The number of patients being diagnosed is increasing each year, particularly in the very young. Despite advances in glucose monitoring and insulin delivery...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Despite evidence that inflammatory mechanisms initiate and complicate pathophysiology in pulmonary arterial hypertension (PAH), no strategies have been developed to target the inflammatory cells involved. Moreover, it has been known for years that autoimmune diseases are associated with certain forms of PAH....

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/15 - 07/31/16

DESCRIPTION (provided by applicant): Neuropathic pain such as diabetic neuropathic pain (DNP) can be difficult to treat with only 30-40% of patients achieving meaningful (>40-50%) pain relief. Current therapies (e.g. duloxeline) mainly address symptoms by focusing on blocking neurotransmission in the pain pathway with limited efficacy, potential...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/II clinical trial of heart failure patients. There is ongoing Phase III trial. In this therapeutic approach, bone marrow-derived mesenchymal stem c...

Load More